Back to Journals » International Journal of Nanomedicine » Volume 9 » Issue 1

Nanopharmaceuticals (part 1): products on the market

Authors Weissig V, Pettinger TK, Murdock N

Received 23 May 2014

Accepted for publication 19 July 2014

Published 15 September 2014 Volume 2014:9(1) Pages 4357—4373

DOI https://doi.org/10.2147/IJN.S46900

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Volkmar Weissig,1 Tracy K Pettinger,2 Nicole Murdock3

1Department of Pharmaceutical Sciences, Midwestern University College of Pharmacy Glendale, Glendale, AZ, USA; 2Department of Pharmacy Practice and Administrative Sciences, College of Pharmacy, Idaho State University, Pocatello, ID, USA; 3Department of Pharmacy Practice, Midwestern University College of Pharmacy Glendale, Glendale, AZ, USA


Abstract: In 2000, the National Institute of Health launched the National Nanotechnology Initiative to support, coordinate, and advance research and development of nanoscale projects. The impact of this new program on health-science related research and development became quickly visible. Broad governmental financial support advanced the start of new, and the deepening of already existing, interdisciplinary research. The anticipated merger of nanoscience with medicine quickly instigated the conceptualization of nanomedicine. The adoption of nanoscience terminology by pharmaceutical scientists resulted in the advent of nanopharmaceuticals. The term “nano” became tantamount to “cutting-edge” and was quickly embraced by the pharmaceutical science community. Colloidal drug delivery systems reemerged as nanodrug delivery systems; colloidal gold became a suspension of nano gold particles. In this review, we first review nanoscience related definitions applied to pharmaceuticals, we then discuss all 43 currently approved drug formulations which are publicized as nanopharmaceuticals, and finally we analyze clinical aspects of selected drug formulations.

Keywords: amphotericin-B, fenofibrate, nanodrugs, nanomedicine, nanoparticle, drug delivery

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Nanopharmaceuticals (part 2): products in the pipeline

Weissig V, Guzman-Villanueva D

International Journal of Nanomedicine 2015, 10:1245-1257

Published Date: 11 February 2015

Readers of this article also read:

Predicting frequent COPD exacerbations using primary care data

Kerkhof M, Freeman D, Jones R, Chisholm A, Price DB

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2439-2450

Published Date: 9 November 2015

Cytotoxicity and physicochemical characterization of iron–manganese-doped sulfated zirconia nanoparticles [Corrigendum]

Al-Fahdawi MQ, Rasedee A, Al-Qubaisi MS, Alhassan FH, Rosli R, El Zowalaty ME, Naadja SE, Webster TJ, Taufiq-Yap YH

International Journal of Nanomedicine 2015, 10:6657-6658

Published Date: 28 October 2015

Fluoromica nanoparticle cytotoxicity in macrophages decreases with size and extent of uptake

Tee N, Zhu Y, Mortimer GM, Martin DJ, Minchin RF

International Journal of Nanomedicine 2015, 10:2363-2375

Published Date: 26 March 2015

Phthalocyanine-loaded graphene nanoplatform for imaging-guided combinatorial phototherapy

Taratula O, Patel M, Schumann C, Naleway MA, Pang AJ, He H, Taratula O

International Journal of Nanomedicine 2015, 10:2347-2362

Published Date: 24 March 2015

Vipegitide: a folded peptidomimetic partial antagonist of α2β1 integrin with antiplatelet aggregation activity

Momic T, Katzhendler J, Shai E, Noy E, Senderowitz H, Eble JA, Marcinkiewicz C, Varon D, Lazarovici P

Drug Design, Development and Therapy 2015, 9:291-304

Published Date: 5 January 2015

A histological evaluation and in vivo assessment of intratumoral near infrared photothermal nanotherapy-induced tumor regression

Green HN, Crockett SD, Martyshkin DV, Singh KP, Grizzle WE, Rosenthal EL, Mirov SB

International Journal of Nanomedicine 2014, 9:5093-5102

Published Date: 5 November 2014

Covalent IR820-PEG-diamine nanoconjugates for theranostic applications in cancer

Fernandez-Fernandez A, Manchanda R, Carvajal DA, Lei T, Srinivasan S, McGoron AJ

International Journal of Nanomedicine 2014, 9:4631-4648

Published Date: 6 October 2014

Preparation, pharmacokinetics and biodistribution of baicalin-loaded liposomes

Wei Y, Guo J, Zheng X, Wu J, Zhou Y, Yu Y, Ye Y, Zhang L, Zhao L

International Journal of Nanomedicine 2014, 9:3623-3630

Published Date: 1 August 2014

Release profile and stability evaluation of optimized chitosan/alginate nanoparticles as EGFR antisense vector

Ebrahim Azizi, Alireza Namazi, Ismaeil Haririan, et al

International Journal of Nanomedicine 2010, 5:455-461

Published Date: 29 June 2010